The global organoids market was valued at US$1.28 billion in 2023. The market value is expected to reach US$4.22 billion by 2029. Organoids are three-dimensional (3D) miniature, organ-like structures grown from stem cells that mimic the architecture and function of human organs. Unlike traditional two-dimensional cell cultures, organoids are self-organizing, complex structures that more closely replicate the physiological conditions of actual tissues and organs. This makes them incredibly valuable for studying human development, disease mechanisms, and drug responses.
In the forthcoming years, the organoid market is expected to continue growing due to several converging trends. One key factor is the increasing investment in research and development by pharmaceutical companies and research institutions to leverage organoids for drug discovery and precision medicine applications. The emergence of personalized medicine, which aims to tailor treatments based on individual genetic profiles, has spurred the adoption of organoids, particularly in the field of oncology. Technological advancements in stem cell research, CRISPR gene editing, and bioengineering are also expected to propel the market forward. The market is expected to grow at a CAGR of approx. 22% during the forecasted period of 2024-2029.
Organoids derived from intestinal stem cells closely mimic the architecture and functionality of the human intestine, providing an ideal platform for studying disease mechanisms, drug responses, and microbiome interactions. On the other hand, stomach organoids provide a powerful tool for researchers to model gastric physiology and pathophysiology, enabling the study of disease mechanisms and the development of new therapeutic strategies. These organoids can be used to investigate the effects of specific diets and dietary components on gastric health, which is crucial given the increasing awareness of the role nutrition plays in preventing and managing gastric disorders.
By Application: The report provide the bifurcation of global organoids market based on the following application: Developmental Biology Disease, Drug Discovery and Personalized Medicine, Regenerative Medicine, Pathology of Infectious Disease, Drug Toxicity and Efficacy Testing, and Others. The developmental biology disease segment held the highest share of the market, whereas the drug discovery and personalized medicine segment is expected to be the fastest-growing segment in the forecasted period. The demand for organoids in developmental biology is increasing due to their ability to provide valuable insights into the mechanisms of organogenesis and the developmental processes underlying various diseases.
Organoids, derived from stem cells, closely mimic the architecture and functionality of actual organs, allowing researchers to study how tissues develop and how genetic and environmental factors can influence these processes. On the other hand, the rising demand for organoids in drug discovery and personalized medicine is primarily attributed to their potential to enhance the efficacy and safety of therapeutic interventions.
Organoids can be generated from patient-specific cells, allowing for the development of models that closely resemble an individual’s unique biology. This capability enables researchers to perform drug screening and assess the effectiveness of various compounds in a personalized context, thus providing insights into how different patients may respond to treatments.
By Source: The report provides the glimpse of the global organoids market based on the following sources: Pluripotent Stem Cells and Organ-specific Adult Stem Cells. Pluripotent stem cells held the highest share of the market and is expected to be the fastest-growing segment in the forecasted period. The demand for organoids derived from pluripotent stem cells is experiencing significant growth due to their remarkable potential to differentiate into virtually any cell type in the human body.
Pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells (iPSCs), provide a versatile platform for generating organoids that closely mimic the structure and function of various organs. This capability is particularly advantageous in the field of regenerative medicine, where the ability to produce patient-specific organoids can facilitate personalized treatment strategies and enhance the understanding of disease mechanisms.
By Type: Based on type, the market can be bifurcated into three segments: Consumables, Instruments, and Services. Consumables held the highest share of the market and is expected to be the fastest-growing segment in the forecasted period. The demand for consumables in the organoid market is experiencing growth due to their crucial role in supporting organoid development, maintenance, and experimentation.
Consumables such as culture media, growth factors, extracellular matrices, reagents, and specialized supplements are essential for creating and sustaining organoid cultures. As research and clinical applications involving organoids continue to expand, the need for high-quality consumables that ensure the proper growth, differentiation, and functionality of organoids is increasing.
By End-User: On the basis of end-user, the global organoids market can be divided into four segments namely, Biotechnology and Pharmaceutical Companies, Academic and Research Institutes, Hospitals and Diagnostic Centers, and Other End-Users. Biotechnology and pharmaceutical companies held the highest share of the market and is expected to be the fastest-growing segment in the forecasted period.
The demand for organoids among biotechnology and pharmaceutical companies is rapidly increasing due to their potential to revolutionize drug discovery, development, and personalized medicine. Organoids offer these companies highly accurate, human-relevant models for testing drug efficacy, toxicity, and disease mechanisms, which can significantly reduce the reliance on animal models and 2D cell cultures that often fail to predict human responses.
By Region: The report provides insight into the organoids market based on the regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the major share of the market. In the US, the growth of the organoid market has been particularly pronounced due to several factors. First, the country has the largest pharmaceutical and biotechnology sectors in the world, with substantial investment in R&D aimed at improving drug discovery and precision medicine.
The US government, through agencies like the National Institutes of Health (NIH), has been heavily funding research on organoids, boosting their development and adoption. The country’s advanced healthcare system, which emphasizes early disease detection and personalized treatment, further accelerates the demand for innovative organoid-based solutions.
Germany has emerged as a leader in the European organoid market due to its strong biotechnology sector, robust healthcare infrastructure, and heavy investment in medical research. The country is renowned for its advanced research institutions, such as the Max Planck Institute and Helmholtz Association, which are at the forefront of stem cell and organoid research. Germany’s commitment to innovation is further bolstered by significant government funding, such as through the Federal Ministry of Education and Research (BMBF), supporting initiatives in regenerative medicine and biotechnology.
China, as one of the leading markets in the Asia Pacific, has been experiencing a surge in organoid research and applications, driven by the country’s ambitious healthcare reforms and strong focus on biotechnology innovation. The Chinese government has made significant investments in biomedical research through initiatives like “Made in China 2025,” which emphasizes advancements in biotechnology and healthcare innovation. China’s vast pharmaceutical industry is increasingly integrating organoid technology into its drug discovery pipeline to reduce the reliance on animal testing and improve the accuracy of preclinical drug trials.
Stem cells, particularly induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), have the unique ability to differentiate into various cell types, allowing scientists to generate organ-specific tissues that closely mimic human organs. With the progress in stem cell technology, researchers are now able to create organoids that replicate the structure and function of organs like the brain, liver, lungs, and kidneys with greater precision. These advancements have expanded the applications of organoids in drug discovery, disease modeling, personalized medicine, and regenerative therapies.
Challenges: However, the market growth would be negatively impacted by various challenges such as lack of skilled professionals, issues related to incorporation of organoid into existing workforce, etc.
Trends: The market is projected to grow at a fast pace during the forecast period, due to increasing focus on drug discovery and development, combining organoid with organ-on-a-chip, advancement in biotechnology, technological innovations in 3D cell culture, etc. Organoid and organ-on-a-chip, which serve as evolving pathological and human physiological relevant in vitro models, have the potential to revolutionize the conventional paradigm of cancer research and produce real clinical benefits.
The recent inclination in the collaborative application of organoids with organ-on-a-chip and 3D bioprinting enables the development of sophisticated cancer models to study underlying mechanisms of tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment interactions. By incorporating multiple organoids into organ-on-a-chip, organoid-on-a-chip can inherit benefits of both organoid and organ-on-a-chip and provide a valuable tool to study multiorgan tumor metastases and cancer-microenvironment interactions.
In the forthcoming years, the organoid market is expected to continue growing due to several converging trends. One key factor is the increasing investment in research and development by pharmaceutical companies and research institutions to leverage organoids for drug discovery and precision medicine applications. The emergence of personalized medicine, which aims to tailor treatments based on individual genetic profiles, has spurred the adoption of organoids, particularly in the field of oncology. Technological advancements in stem cell research, CRISPR gene editing, and bioengineering are also expected to propel the market forward. The market is expected to grow at a CAGR of approx. 22% during the forecasted period of 2024-2029.
Market Segmentation Analysis:
By Organ Type: The report provides the bifurcation of the global organoids market based on the organ type: Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others. The intestine segment held the highest share of the market, whereas stomach segment is expected to be the fastest-growing segment in the forecasted period. The organoid market for intestinal models is experiencing significant growth due to the increasing prevalence of gastrointestinal diseases and disorders, such as inflammatory bowel disease (IBD), colorectal cancer, and celiac disease.Organoids derived from intestinal stem cells closely mimic the architecture and functionality of the human intestine, providing an ideal platform for studying disease mechanisms, drug responses, and microbiome interactions. On the other hand, stomach organoids provide a powerful tool for researchers to model gastric physiology and pathophysiology, enabling the study of disease mechanisms and the development of new therapeutic strategies. These organoids can be used to investigate the effects of specific diets and dietary components on gastric health, which is crucial given the increasing awareness of the role nutrition plays in preventing and managing gastric disorders.
By Application: The report provide the bifurcation of global organoids market based on the following application: Developmental Biology Disease, Drug Discovery and Personalized Medicine, Regenerative Medicine, Pathology of Infectious Disease, Drug Toxicity and Efficacy Testing, and Others. The developmental biology disease segment held the highest share of the market, whereas the drug discovery and personalized medicine segment is expected to be the fastest-growing segment in the forecasted period. The demand for organoids in developmental biology is increasing due to their ability to provide valuable insights into the mechanisms of organogenesis and the developmental processes underlying various diseases.
Organoids, derived from stem cells, closely mimic the architecture and functionality of actual organs, allowing researchers to study how tissues develop and how genetic and environmental factors can influence these processes. On the other hand, the rising demand for organoids in drug discovery and personalized medicine is primarily attributed to their potential to enhance the efficacy and safety of therapeutic interventions.
Organoids can be generated from patient-specific cells, allowing for the development of models that closely resemble an individual’s unique biology. This capability enables researchers to perform drug screening and assess the effectiveness of various compounds in a personalized context, thus providing insights into how different patients may respond to treatments.
By Source: The report provides the glimpse of the global organoids market based on the following sources: Pluripotent Stem Cells and Organ-specific Adult Stem Cells. Pluripotent stem cells held the highest share of the market and is expected to be the fastest-growing segment in the forecasted period. The demand for organoids derived from pluripotent stem cells is experiencing significant growth due to their remarkable potential to differentiate into virtually any cell type in the human body.
Pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells (iPSCs), provide a versatile platform for generating organoids that closely mimic the structure and function of various organs. This capability is particularly advantageous in the field of regenerative medicine, where the ability to produce patient-specific organoids can facilitate personalized treatment strategies and enhance the understanding of disease mechanisms.
By Type: Based on type, the market can be bifurcated into three segments: Consumables, Instruments, and Services. Consumables held the highest share of the market and is expected to be the fastest-growing segment in the forecasted period. The demand for consumables in the organoid market is experiencing growth due to their crucial role in supporting organoid development, maintenance, and experimentation.
Consumables such as culture media, growth factors, extracellular matrices, reagents, and specialized supplements are essential for creating and sustaining organoid cultures. As research and clinical applications involving organoids continue to expand, the need for high-quality consumables that ensure the proper growth, differentiation, and functionality of organoids is increasing.
By End-User: On the basis of end-user, the global organoids market can be divided into four segments namely, Biotechnology and Pharmaceutical Companies, Academic and Research Institutes, Hospitals and Diagnostic Centers, and Other End-Users. Biotechnology and pharmaceutical companies held the highest share of the market and is expected to be the fastest-growing segment in the forecasted period.
The demand for organoids among biotechnology and pharmaceutical companies is rapidly increasing due to their potential to revolutionize drug discovery, development, and personalized medicine. Organoids offer these companies highly accurate, human-relevant models for testing drug efficacy, toxicity, and disease mechanisms, which can significantly reduce the reliance on animal models and 2D cell cultures that often fail to predict human responses.
By Region: The report provides insight into the organoids market based on the regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the major share of the market. In the US, the growth of the organoid market has been particularly pronounced due to several factors. First, the country has the largest pharmaceutical and biotechnology sectors in the world, with substantial investment in R&D aimed at improving drug discovery and precision medicine.
The US government, through agencies like the National Institutes of Health (NIH), has been heavily funding research on organoids, boosting their development and adoption. The country’s advanced healthcare system, which emphasizes early disease detection and personalized treatment, further accelerates the demand for innovative organoid-based solutions.
Germany has emerged as a leader in the European organoid market due to its strong biotechnology sector, robust healthcare infrastructure, and heavy investment in medical research. The country is renowned for its advanced research institutions, such as the Max Planck Institute and Helmholtz Association, which are at the forefront of stem cell and organoid research. Germany’s commitment to innovation is further bolstered by significant government funding, such as through the Federal Ministry of Education and Research (BMBF), supporting initiatives in regenerative medicine and biotechnology.
China, as one of the leading markets in the Asia Pacific, has been experiencing a surge in organoid research and applications, driven by the country’s ambitious healthcare reforms and strong focus on biotechnology innovation. The Chinese government has made significant investments in biomedical research through initiatives like “Made in China 2025,” which emphasizes advancements in biotechnology and healthcare innovation. China’s vast pharmaceutical industry is increasingly integrating organoid technology into its drug discovery pipeline to reduce the reliance on animal testing and improve the accuracy of preclinical drug trials.
Market Dynamics:
Growth Drivers: The global organoids market has been growing over the past few years, due to factors such as increasing demand for tumor modeling and biobanking, growing adoption of personalized drugs, rising focus on developing alternatives for animal testing models, advancements in stem cell research, rising investment in research and development (R&D), growing adoption in toxicology testing, growing collaborations and partnerships, and many other factors. Advancements in stem cell research are pivotal to the growth of the organoid market, as they enable the development of more complex and physiologically accurate organoid models.Stem cells, particularly induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), have the unique ability to differentiate into various cell types, allowing scientists to generate organ-specific tissues that closely mimic human organs. With the progress in stem cell technology, researchers are now able to create organoids that replicate the structure and function of organs like the brain, liver, lungs, and kidneys with greater precision. These advancements have expanded the applications of organoids in drug discovery, disease modeling, personalized medicine, and regenerative therapies.
Challenges: However, the market growth would be negatively impacted by various challenges such as lack of skilled professionals, issues related to incorporation of organoid into existing workforce, etc.
Trends: The market is projected to grow at a fast pace during the forecast period, due to increasing focus on drug discovery and development, combining organoid with organ-on-a-chip, advancement in biotechnology, technological innovations in 3D cell culture, etc. Organoid and organ-on-a-chip, which serve as evolving pathological and human physiological relevant in vitro models, have the potential to revolutionize the conventional paradigm of cancer research and produce real clinical benefits.
The recent inclination in the collaborative application of organoids with organ-on-a-chip and 3D bioprinting enables the development of sophisticated cancer models to study underlying mechanisms of tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment interactions. By incorporating multiple organoids into organ-on-a-chip, organoid-on-a-chip can inherit benefits of both organoid and organ-on-a-chip and provide a valuable tool to study multiorgan tumor metastases and cancer-microenvironment interactions.
Impact Analysis of COVID-19 and Way Forward:
While the pandemic initially created operational challenges, it ultimately accelerated the adoption and validation of organoids as a key tool in biomedical research, leading to greater investment and interest in their applications beyond COVID-19. The post-pandemic era has seen the organoids market thrive, benefiting from increased investment, technological innovation, and the broader recognition of their value in both therapeutic development and disease modeling.Competitive Landscape:
The global organoids market is fragmented in nature. The key players in the global organoids market are:- Danaher Corporation (Molecular Devices, LLC)
- Thermo Fisher Scientific Inc.
- Merck Group
- Corning Incorporated
- Charles River Laboratories International, Inc.
- DefiniGEN Limited
- InSphero
- STEMCELL Technologies
- HUB Organoids
- Mimetas
- Organoid Therapeutics
- 3Dnamics
Table of Contents
1. Executive Summary
2. Introduction
3. Global Market Analysis
4. Regional Market Analysis
5. Impact of COVID-19
6. Market Dynamics
7. Competitive Landscape
8. Company Profiles
List of Figures
Companies mentioned
Some of the key companies profiled in this Global Organoids Market report include:- Danaher Corporation (Molecular Devices, LLC)
- Thermo Fisher Scientific Inc.
- Merck Group
- Corning Incorporated
- Charles River Laboratories International, Inc.
- DefiniGEN Limited
- InSphero
- STEMCELL Technologies
- HUB Organoids
- Mimetas
- Organoid Therapeutics
- 3Dnamics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 191 |
| Published | October 2024 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 1.56 Billion |
| Forecasted Market Value ( USD | $ 4.22 Billion |
| Compound Annual Growth Rate | 22.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
